Citigroup Inc Enochian Biosciences Inc Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Citigroup Inc holds 61,012 shares of ENOB stock, worth $280,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,012

Previous 16,442 271.07%

Holding current value

$280,655

Previous $75,000 273.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	N/A	44,570 Added 271.07%	61,012 $280,000
Q2 2024 Aug 12, 2024	SELL	N/A	-171,012 Reduced 91.23%	16,442 $75,000
Q1 2024 May 10, 2024	BUY	N/A	136,525 Added 268.07%	187,454 $862,000
Q4 2023 Feb 09, 2024	BUY	$4.3 - $4.7 $139,887 - $152,900	32,532 Added 176.83%	50,929 $234,000
Q3 2023 Nov 09, 2023	BUY	$0.0 - $4.46 $0 - $82,037	18,394 Added 613133.31%	18,397 $82,000
Q2 2023 Aug 10, 2023	SELL	$0.4 - $1.3 $301 - $978	-753 Reduced 99.6%	3 $0
Q1 2023 May 11, 2023	SELL	$0.91 - $1.31 $1,042 - $1,501	-1,146 Reduced 60.25%	756 $0
Q4 2022 Feb 09, 2023	BUY	$1.03 - $2.13 $1,650 - $3,412	1,602 Added 534.0%	1,902 $1,000
Q3 2022 Nov 10, 2022	SELL	$1.7 - $2.86 $48,341 - $81,326	-28,436 Reduced 98.96%	300 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.93 - $8.73 $2,190 - $9,908	-1,135 Reduced 3.8%	28,736 $55,000
Q1 2022 May 12, 2022	BUY	$4.42 - $9.0 $88,360 - $179,919	19,991 Added 202.34%	29,871 $246,000
Q4 2021 Feb 10, 2022	BUY	$6.71 - $12.55 $60,899 - $113,903	9,076 Added 1128.86%	9,880 $72,000
Q3 2021 Nov 10, 2021	BUY	$4.56 - $7.88 $3,666 - $6,335	804 New	804 $5,000

Others Institutions Holding ENOB

# of Institutions

Shares Held

14.7M

Call Options Held

24K

Put Options Held

19.1K

View Full List

About Enochian Biosciences Inc

Ticker ENOB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,950,000
Market Cap $244M
Description
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...

More about ENOB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account